Author(s):
Arrum Rizky Andreani, Muhammad Ihwan Narwanto, Pipiet Wulandari, Wiwien Sugih Utami, Heni Fatmawati
Email(s):
muhammadnarwanto@unej.ac.id
DOI:
10.52711/0974-360X.2025.00205 
Address:
Arrum Rizky Andreani1, Muhammad Ihwan Narwanto2*, Pipiet Wulandari3, Wiwien Sugih Utami4, Heni Fatmawati5
1Faculty of Medicine, Jember University.
2Department of Anatomy, Faculty of Medicine, Jember University.
3Department of Cardiology, Faculty of Medicine, Jember University.
4Department of Parasitology, Faculty of Medicine, Jember University.
5Department of Radiology, Faculty of Medicine, Jember University.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2025
ABSTRACT:
Neuroblastoma (NB) is an embryonic tumor of the sympathetic nervous system and, based on its histology, is thought to arise from a failure of sympathoadrenal 5 progenitor cells to differentiate. Despite aggressive and multi-modal therapies (i.e chemotherapy, radiation therapy, surgery, and stem cell transplantation), the effective treatment of advanced NB is still a challenge for pediatric oncology and so alternative treatments are needed. Molecular-based or gene therapy, especially silencing RNA (siRNA) is currently becoming popular for various kinds of therapies, including for neuroblastoma. The use of siRNA therapy in neuroblastoma models has been shown to reduce tumor volume, by inducing apoptosis and inhibiting tumor growth. This study aimed to prove that gene suppression by siRNA can induce apoptosis and inhibit tumorigenesis in neuroblastoma models. This study is a non-experimental study with a systematic review method without being followed by meta-analysis, which is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). The results of the systematic review showed that there were four articles that showed the effect of siRNA on gene expression levels, and gene silencing by siRNA can induce apoptosis and inhibit tumorigenesis. Of the four articles used, all used different target genes, using CDC20, Bcl-2, MYCN and survivin.
Cite this article:
Arrum Rizky Andreani, Muhammad Ihwan Narwanto, Pipiet Wulandari, Wiwien Sugih Utami, Heni Fatmawati. Gene Suppression by siRNA to Induce Apoptosis and Inhibit Tumor Growth on Neuroblastoma Models: A Systematic Review. Research Journal of Pharmacy and Technology. 2025;18(3):1428-3. doi: 10.52711/0974-360X.2025.00205
Cite(Electronic):
Arrum Rizky Andreani, Muhammad Ihwan Narwanto, Pipiet Wulandari, Wiwien Sugih Utami, Heni Fatmawati. Gene Suppression by siRNA to Induce Apoptosis and Inhibit Tumor Growth on Neuroblastoma Models: A Systematic Review. Research Journal of Pharmacy and Technology. 2025;18(3):1428-3. doi: 10.52711/0974-360X.2025.00205 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-3-66
REFERENCES:
1. Paolo DD. Yang F. Pastorino L. Emionite M. Cilli A. Daga E. Destafanis A et al. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal sirnas against alk. Oncotarget. 2015; 6(30): 28774–28789. doi.org/10.18632/oncotarget.4342.
2. Veschi VZ. Liu TC. Voss L. Ozbun B. Gryder C. Yan Y. Hu A et al. Epigenetic sirna and chemical screens identify setd8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma. Cancer Cell. 2017; 31(1): 50–63. doi.org/10.1016/j.ccell.2016.12.002.
3. Galli S. Naranjo A. Ryn CV. Tilan JU. Trinh E. Yang C. Tsuei J et al. Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma. American Journal of Pathology. 2016; 186(11): 3040–3053. doi.org/10.1016/j.ajpath.2016.07.019.
4. Davenport KP. Blanco. FC. Sandler AD. Pediatric malignancies. neuroblastoma, wilm’s tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma. Surgical Clinics of North America. 2012; 92(3): 745–767. doi.org/10.1016/ j.suc.2012.03.004.
5. Di Paolo D. Ambrogio C. Pastorino F. Brignole C. Martinengo C. Carosio R. Loi M et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Molecular Therapy, 2011; 19(12): 2201–2212. doi.org/10.1038/mt.2011.142.
6. Malik A. RNA therapeutic, pendekatan baru dalam terapi gen. Majalah Ilmu Kefarmasian, 2005; 2(2): 51–61. doi.org/10.7454/psr.v2i2.3384
7. Patil PM. Chaudhari PD. Sahu M. Duragkar NJ. Review Article on Gene Therapy. Research Journal of Pharmacology and Pharmacodynamics. 2012; 4(2):77-83.
8. Gatta AK. Philip NV. Chandrashekhar R. Udupa N. Reddy MS. Mutalik S. Josyula VR. Strategic design of potential siRNA molecules for in vitro Evaluation in ABCG2 resistant Breast cancer and in vivo toxicity Determination. Research J. Pharm. and Tech. 2021; 14(1): 55-61. doi.org/ 10.5958/0974-360X.2021.00011.1.
9. Sajid MI. Moazzam M. Tiwari RK. Kato S. Cho KY. Overcoming barriers for sirna therapeutics: from bench to bedside. Pharmaceuticals. 2020; 13(10): 1–295 25. doi.org/10.3390/ ph13100294.
10. Kaymaz BT. and Kosov B. Advances in therapeutic approaches using rna interference as a gene silencing tool. Advanced Techniques in Biology and Medicine. 2013; 1(2):1–8.doi.org/ 10.4172/2379-1764.1000108.
11. Shen M. Gong F. Pang P. Zhu K. Meng X. Wu C. Wang J et al. An mri-visible non-viral vector for targeted bcl-2 sirna delivery to neuroblastoma. International Journal of Nanomedicine. 2012; 7: 3319–3332.doi.org/10.2147/IJN.S32900.
12. Tagalakis AD. Jayarajan V. Maeshima R. Ho KH. Syed F. Wu LP. Aldossary AM et al. Integrin-targeted, short interfering rna nanocomplexes for neuroblastoma tumor-specific delivery achieve mycn silencing with improved survival. Advanced Functional Materials. 2021; 31(37). doi.org/10.1002/adfm.202104843.
13. Bhunia S. Radha V. Chaudhuri A. CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma. Nanoscale. 2017; 9(3): 1201–1212. doi.org/10.1039/ C6NR07532K.
14. Zhang L. Liang H. Cao W. Xu R. Ju XL. Downregulation of survivin by sirna inhibits invasion and promotes apoptosis in neuroblastoma sh-312 sy5y cells. Brazilian Journal of Medical and Biological Research. 2014; 47(7): 548–553. doi.org/10.1590/1414-431x20143459
15. Shinde S. Saroagi GK. Mishra DK. Nanocarriers for Effective si-RNA delivery. Research J. Pharm. and Tech. 2018; 11(9): 4166-4172. doi.org/ 10.5958/0974-360X.2018.00765.5.
16. Wierzbicki A. Gil M. Ciesielski M. Fenstermaker RA. Kaneko Y. Rokita H. Lau JT et al. Immunization with a mimotope of gd2 ganglioside induces cd8+ t cells that recognize cell adhesion molecules on tumor cells. Journal of Immunology. 2008; 181(9): 6644–6653. doi.org/10.4049/jimmunol.181.9.6644.
17. Manunta MDI. McAnulty RJ. Tagalakis AD. Bottoms SE. Campbell F. Hailes HC. Tabor AB et al. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. Plos One. 2011; 6(10): e26768. doi.org/10.1371/ journal.pone.0026768.
18. Jagani H. Rao JV. Palanimuthu VR. Hariharapura RC. Gang S. A nanoformulation of siRNA and its role in cancer therapy: In vitro and in vivo evaluation. Cellular and Molecular Biology Letters, 2013; 18(1): 120–136.doi.org/10.2478/s11658-012-0043-2.
19. Zhu Q. Feng C. Liao W. Zhang Y. Tang S. Target delivery of mycn sirna by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell International. 2013; 13(1): 1–6. doi.org/10.1186/1475-2867-13-65.
20. Kong LL. Man DM. Wang T. Zhang GA. Cui W. SiRNA targeting rbp2 inhibits expression, proliferation, tumorigenicity and invasion in thyroid carcinoma cells. Oncology Letters. 2015; 10(6): 3393–3398.doi.org/10.3892/ol.2015.3782.
21. Boyapalle S. Xu W. Raulji P. Mohapatra S. Mohapatra SS. A multiple sirna-based anti-hiv/shiv microbicide shows protection in both in vitro and in vivo models. PloS One. 2015; 10(9): e0135288. doi.org/10.1371/journal.pone.0135288.
22. Dyberg C. Fransson S. Andonova T. Sveinbjörnsson B. Lännerholm-Palm J. Olsen TK. Forsberg D et al. Rho-associated kinase is a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2017; 114(32): E6603–E6612.doi.org/10.1073/pnas.1706011114.
23. Maeshima R. Moulding D. Stoker AW. Hart SL. MYCN silencing by rnai induces neurogenesis and suppresses proliferation in models of neuroblastoma with resistance to retinoic acid. Nucleic Acid Therapeutics. 2020; 344 30(4): 237–248. doi.org/10.1089/ nat.2019.0831.
24. Zhou Z. Zhao Y. Gu L. Niu X. Lu S. Inhibiting proliferation and migration of lung cancer using small interfering rna targeting on aldo-keto reductase family member b10. Molecular Medicine Reports. 2018; 17(2): 2153–2160. doi.org/10.3892/ mmr.2017.8173.